FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234853674> ?p ?o ?g. }

• W4234853674 endingPage "2552" @default.
• W4234853674 startingPage "2552" @default.
• W4234853674 abstract "Abstract Cancer immunotherapies have shown remarkable clinical activity across several tumor types but responses have been modest in breast cancers. This is attributed to low levels of neo-antigens in breast tumors and immunosuppressive nature of mammary tumor microenvironment. Here we investigated if we can counteract these obstacles to an effective immunotherapy by inducing senescence in breast cancer cells. Senescence is one of the physiological stress response programs characterized by loss of proliferative potential and secretion of a variety of pro-inflammatory markers which promotes identification and removal of senescent cells by the immune cells. Here we hypothesized that senescence will stimulate anti-tumor immune response by establishing immune-permissive microenvironment. We utilized immunocompetent and humanized PDX-bearing mice to investigate senescence-induced modulation of tumor secretome proteome, transcriptome and immune cell recruitment and activity. An FDA-approved small molecule CDK4/6 inhibitor was used to induce senescence. We detected induction of multiple markers of senescence after CDK4/6 inhibitor treatment of cells and tumors. Senescent cells and tumors had increased secretion of chemokines CCL4, CCL5, CXCL9, CXCL10 and CXCL11 which facilitated T cell homing into the tumor. This was a result of their transcriptional induction by NF-κB. Consequently, we observed the dynamic enrichment of tumor immune microenvironment with T cells in tumors treated with CDK4/6 inhibitor. Furthermore, the recruitment of adoptively transferred ex-vivo activated anti-tumor T cells was significantly enhanced in tumors that were treated with CDK4/6 inhibitor. Finally, CDK4/6 inhibitor-treated tumors became responsive to T cell-activating immunotherapy with antibody agonists of T cell co-stimulatory receptors OX40 and 4-1BB. In summary, our findings suggest that CDK4/6 inhibition can facilitate T cell recruitment into the mammary tumors which can lead to an improved immunotherapy response. This pre-clinical study provides rationale for clinical development of CDK4/6 inhibitors and T cell agonists and uncovers the potential of senescence-inducing approach for sensitizing tumors to immune therapy. Citation Format: Ashlyn Blevins, Stacey Mont, Hunter Lawrence, Nabil Saleh, Sheau-Chiann Chen, Ann Richmond, Anna Vilgelm. Senescence induced by CDK4/6 inhibition facilitates anti-tumor T cell responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2552." @default.
• W4234853674 created "2022-05-12" @default.
• W4234853674 creator A5008289866 @default.
• W4234853674 creator A5010542605 @default.
• W4234853674 creator A5012688242 @default.
• W4234853674 creator A5041805037 @default.
• W4234853674 creator A5059563188 @default.
• W4234853674 creator A5060947046 @default.
• W4234853674 creator A5076757523 @default.
• W4234853674 date "2019-07-01" @default.
• W4234853674 modified "2023-09-27" @default.
• W4234853674 title "Abstract 2552: Senescence induced by CDK4/6 inhibition facilitates anti-tumor T cell responses" @default.
• W4234853674 doi "https://doi.org/10.1158/1538-7445.am2019-2552" @default.
• W4234853674 hasPublicationYear "2019" @default.
• W4234853674 type Work @default.
• W4234853674 citedByCount "0" @default.
• W4234853674 crossrefType "journal-article" @default.
• W4234853674 hasAuthorship W4234853674A5008289866 @default.
• W4234853674 hasAuthorship W4234853674A5010542605 @default.
• W4234853674 hasAuthorship W4234853674A5012688242 @default.
• W4234853674 hasAuthorship W4234853674A5041805037 @default.
• W4234853674 hasAuthorship W4234853674A5059563188 @default.
• W4234853674 hasAuthorship W4234853674A5060947046 @default.
• W4234853674 hasAuthorship W4234853674A5076757523 @default.
• W4234853674 hasConcept C13373296 @default.
• W4234853674 hasConcept C203014093 @default.
• W4234853674 hasConcept C2776107976 @default.
• W4234853674 hasConcept C502942594 @default.
• W4234853674 hasConcept C522857546 @default.
• W4234853674 hasConcept C86803240 @default.
• W4234853674 hasConcept C8891405 @default.
• W4234853674 hasConcept C95444343 @default.
• W4234853674 hasConceptScore W4234853674C13373296 @default.
• W4234853674 hasConceptScore W4234853674C203014093 @default.
• W4234853674 hasConceptScore W4234853674C2776107976 @default.
• W4234853674 hasConceptScore W4234853674C502942594 @default.
• W4234853674 hasConceptScore W4234853674C522857546 @default.
• W4234853674 hasConceptScore W4234853674C86803240 @default.
• W4234853674 hasConceptScore W4234853674C8891405 @default.
• W4234853674 hasConceptScore W4234853674C95444343 @default.
• W4234853674 hasIssue "13_Supplement" @default.
• W4234853674 hasLocation W42348536741 @default.
• W4234853674 hasOpenAccess W4234853674 @default.
• W4234853674 hasPrimaryLocation W42348536741 @default.
• W4234853674 hasRelatedWork W2005666125 @default.
• W4234853674 hasRelatedWork W2050374169 @default.
• W4234853674 hasRelatedWork W2056124145 @default.
• W4234853674 hasRelatedWork W2511201656 @default.
• W4234853674 hasRelatedWork W3029416930 @default.
• W4234853674 hasRelatedWork W3030649553 @default.
• W4234853674 hasRelatedWork W4280622011 @default.
• W4234853674 hasRelatedWork W4303699841 @default.
• W4234853674 hasRelatedWork W4307275404 @default.
• W4234853674 hasRelatedWork W4317584583 @default.
• W4234853674 hasVolume "79" @default.
• W4234853674 isParatext "false" @default.
• W4234853674 isRetracted "false" @default.
• W4234853674 workType "article" @default.